CD38 and lymphoma: As the diagnostic component, the Zr‐89‐labeled mAb is highly specific in delineating CD38‐positive lymphoma via positron emission tomography imaging, while the Lu‐177‐labeled mAb serves well as the therapeutic component to suppress tumor after a one‐time administration.